Author: Mark Du Bois

On Friday 15 December, Ziccum crowned a successful year with a 2023 summary and seasonal celebration.

The Management Team presented a strategic review of 2024’s milestones, and the year ahead. Colleagues then enjoyed a ‘Glöggmingel’ complete with traditional Swedish spiced mulled wine and present opening around the tree, before heading out to dinner at a lovely French–themed restaurant in Malmö, southern Sweden.

CEO Ann Gidner: “it was great for us to gather together and really appreciate everything we’ve accomplished. You couldn’t wish for a better team!”

On Dec’ 11 Ziccum won extensive interest in its unique technology for formulating and drying liquid biologics, LaminarPace, from a specialist audience of international  inhaled drug development scientists from Europe, the US and Asia. The event, industry webinar ‘Inhaled Biologics’, was organized by Inhalation Sciences AB.

The webinar was the latest in a series organized by Inhalation Sciences, each one co-hosted by an invited expert, this time Ziccum. Ziccum COO Xavier Turon presented LaminarPace and the latest data on its formulation and drying of liquid mRNA/LNP into bioactive thermostable dry powder.

CEO Ann Gidner and Scientific Director Fabrice Rose took the dynamic Q&A session, which drew many enquiring and detailed questions from the specialist audience of scientists working in inhaled drug development

The Webinar included a Case Study by Inhalation Sciences CSO Assoc Prof Per Gerde, the original inventor of LaminarPace.

CEO Ann Gidner: “it was a pleasure to take part and to hear the clear interest of participants in a solution that can enable new delivery forms and solve many of the stability challenges of next-generation Biologics”.

Ziccum heads West in 2024, Jan 6 – 11, San Francisco. Book now to meet Ziccum and hear the latest news and data on our thermostable mRNA/LNP projects and unique formulation & drying technology, that turns liquid biologics into robust powders needing no cryogenic storage or delicate handling.

On January 6–7, CEO Ann Gidner attends the exclusive Longwood Healthcare Leaders CEO conference, joining Biotech CEOs, KOLs and investors for off-the-record discussions to drive collaboration and accelerate investment in healthcare.

On January 8–11, CEO Ann Gidner attends theJPMorgan Annual Healthcare Conference week, the most important gathering of Pharmaceutical Industry leaders and healthcare investors in the US. Meetings are booked with existing and potential new Partner Corporations and their leadership representatives.

MAJOR US INTEREST. Ziccum attended events in the US in June, July and October in 2023, generating significant interest in its unique technology that has landed three major Feasibility agreements with industry leaders in the last six months.

Book a meeting here.

Ziccum had an intensive schedule of meetings at Nordic Life Science, Copenhagen November 29 – 30.

CEO Ann Gidner and Chairman Fredrik Sjövall were invited to partnering meetings with new interested prospects and attended valuable follow-up meetings.

CEO: ‘the knowledge of our offering is high and we expect to pursue many dialogues initiated here. It’s very satisfying we could move dialogues to a more strategic level with large corporation counterparts. We’d like to thank our industry colleagues for an engaging, well-attended event”.

A new presentation by Ziccum CEO Ann Gidner describes how new robust formulations of mRNA/LNP vaccines and therapeutics that do not require cryogenic storage or special handling can be generated by the company’s unique technology with particle properties and vaccine activity intact. It follows the company’s recent announcement of a third industry Feasibility Study, with a Biomanufacturing corporation specializing in vaccines.

Watch the BioStock presentation here.

The presentation – ‘Enabling Delivery & Solving Stability for Biologics and mRNA’ – describes the outstanding potential of the company’s technology in todays ‘new mRNA era’ in biopharmaceuticals.

The company has now signed three funded collaborations with major Pharma or Biopharma corporations evaluating its LaminarPace system. Two of the projects are on mRNA/LNP materials and one for lentiviruses.

Are you a formulation scientist trying to develop new, more stable formulations of biopharmaceuticals? On Monday Dec 11 Ziccum experts are special guests at a live scientific webinar on ‘Inhaled Biologics’ with inhalation Key Opinion Leader Assoc. Prof. Per Gerde. Ziccum COO Xavier Turon  and CEO Ann Gidner will take part.

The webinar will cover: i) how LaminarPace, Ziccum’s Mass Transfer technology, uniquely formulates and dries biologics, without exposing them to extreme temperatures, as stable, bioactive dry powders that are highly suited for inhalation, and ii) Preclinical Testing solutions for Inhalable Formulations.

The Webinar is part of a series for industry developers hosted by Inhalation Sciences AB. This session, part of that series, is titled “INHALED BIOLOGICS: Realization and Preclinical Testing of Dry Powder Formulations”.

Inhalable solid dose forms of biologics including next-generation mRNA vaccines are of great interest to the biopharmaceutical industry at the moment, promising increased storage stability, simplified patient administration and an ability to stimulate the mucosal immune system. LaminarPace was originally developed by Associate Professor Gerde specifically to dry liquid biologics for inhalation.

You can Register and Enroll for the Webinar here.

Meet Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall at Nordic Life Science Days 29-30 November, Copenhagen.

Discuss new stability and delivery solutions for next-generation Biotherapeutics. Want to expand what’s possible for your delicate biologic APIs? Meet Ziccum at #nlsdays!

Contact Ziccum here. 

On Thursday November 9 Ziccum were at an all-day workshop at the Research Center for Pharmaceutical Engineering in Graz, a global leader in pharmaceutical process engineering, organized by advanced process engineering simulation experts Simvantage.

ZHAW / ICP, Ziccum’s partners in the Eurostars project developing an industrial digital simulation of LaminarPace, attended, along with Ziccum’s Scientific Director Fabrice Rose and Chief Operating Officer Xavier Turon.

Ziccum continues to develop core capabilities and components of LaminarPace to optimize industrial integration and scale-out. Right now, the focus is on the powder collector and nebulizer function.

Ziccum CEO Ann Gidner and Chairman Fredrik Sjövall enjoyed a packed schedule of quality meetings at the BIO-Europe Partnering Conference this week, with close to 6,000 pharma and biopharma professionals attending.

The event ran from Nov 5 – 8 in Munich, Germany. Ziccum held follow-up meetings with existing partners, new business meetings and discussions with a wide range of new contacts.

CEO Ann Gidner: “We had a very productive conference. With both valuable business dialogues and industry intelligence, this is of great value to Ziccum. Celebrating our new Evaluation Agreement signing on Day 2 was also memorable!”

Read about Ziccum’s latest Evaluation Agreement here

.       

.